BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23842228)

  • 1. [ALK inhibitor].
    Sakamoto H
    Nihon Yakurigaku Zasshi; 2013 Jul; 142(1):48-50. PubMed ID: 23842228
    [No Abstract]   [Full Text] [Related]  

  • 2. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
    Costa DB
    J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
    [No Abstract]   [Full Text] [Related]  

  • 3. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
    Costa DB; Kobayashi S
    J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
    [No Abstract]   [Full Text] [Related]  

  • 4. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ; Shapiro GI
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma.
    Salvi S; Varesano S; Boccardo S; Ravetti JL; Canessa PA; Pistillo MP; Ferro P; Fedeli F; Roncella S
    J Thorac Oncol; 2017 Aug; 12(8):e116-e118. PubMed ID: 28748818
    [No Abstract]   [Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N; Santarpia M; Gonzalez Cao M; Teixido C; Sosa AE; Berenguer J; Rodriguez Capote A; Altavilla G; Rosell R
    Expert Opin Investig Drugs; 2017 Jun; 26(6):713-722. PubMed ID: 28463570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL; Wenger SD; Kim M; Thompson LA
    Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Crizotinib: At last in first-line treatment of advanced-stage ALK-rearranged non-small cell lung cancer].
    Giroux Leprieur E; Wislez M
    Bull Cancer; 2016 Feb; 103(2):125-6. PubMed ID: 26822904
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted treatment tested as potential cancer cure.
    Hayden EC
    Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
    [No Abstract]   [Full Text] [Related]  

  • 10. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
    Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
    Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA; Bubendorf L; Stahel R; Peters S
    Expert Rev Anticancer Ther; 2013 May; 13(5):625-36. PubMed ID: 23617353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G; Seto T
    Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Looking for a new panacea in ALK-rearranged NSCLC: may be Ceritinib?
    Rolfo C; Passiglia F; Russo A; Pauwels P
    Expert Opin Ther Targets; 2014 Sep; 18(9):983-5. PubMed ID: 24998601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-over-it's a feature, not a bug.
    Engelsberg A
    Ann Oncol; 2015 Sep; 26(9):2000-2002. PubMed ID: 26078468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
    Girard N; Audigier-Valette C; Cortot AB; Mennecier B; Debieuvre D; Planchard D; Zalcman G; Moro-Sibilot D; Cadranel J; Barlési F
    Expert Rev Anticancer Ther; 2015 Feb; 15(2):225-33. PubMed ID: 25413260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders.
    Roskoski R
    Expert Opin Drug Discov; 2013 Sep; 8(9):1165-79. PubMed ID: 23805942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid response of brain metastasis to crizotinib in a patient with ALK rearrangement-positive non-small-cell lung cancer.
    Kaneda H; Okamoto I; Nakagawa K
    J Thorac Oncol; 2013 Apr; 8(4):e32-3. PubMed ID: 23486271
    [No Abstract]   [Full Text] [Related]  

  • 19. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1005-13. PubMed ID: 27232673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of the anaplastic lymphoma kinase.
    Mologni L
    Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.